2-[18F]FELP, a novel LAT1-specific PET tracer, for the discrimination between glioblastoma, radiation necrosis and inflammation

Verhoeven, Jeroen; Baguet, Tristan; Piron, Sarah; Pauwelyn, Glenn; Bouckaert, Charlotte; Descamps, Benedicte; Raedt, Robrecht; Vanhove, Christian; Vos, Filip De; Goethals, Ingeborg

doi:10.1016/j.nucmedbio.2019.12.002

Cited by 12 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alterations in the integrity of the blood-brain barrier in inflamed sites leads to immune cell infiltration, fluid transudation into the interstitial space and brain edema. Infiltrated immune cells and reactive glial cells increase expression of mediators, amplifying the response [31,[34][35][36].…”

Section: Neuroinflammation As a Consequence Of Gbm Treatmentmentioning

confidence: 99%

“…A study with 50 patients showed that ( 11 )C-methionine-PET was superior to both ( 11 )Ccholine and F 18 -fluorodeoxyglucose-PET for distinguishing GBM recurrence from radiation necrosis [52]. L-type amino acid transporter 1 (LAT1) tumor-specific PET tracer 2-[ 18 F]-2-fluoroethyl-L-phenylalanine PET is able to differentiate GBM from radiation necrosis and 2-2-[ 18 F]-2-f luoroethyl-L-phenylalanine uptake is less likely to be contaminated by the presence of inflammation than the F 18 fluorodeoxyglucose signal [35] (Table 1).…”

Section: Imaging Advances For the Evaluation Of Brain Tumors And Neuroinflammationmentioning

confidence: 99%

See 1 more Smart Citation

Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches

Roesler

Dini²,

Isolan³

2021

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Brain tumors and brain metastases induce changes in brain tissue remodeling that lead to immunosuppression and trigger an inflammatory response within the tumor microenvironment. These immune and inflammatory changes can influence invasion and metastasis. Other neuroinflammatory and necrotic lesions may occur in patients with brain cancer or brain metastases as sequelae from treatment with radiotherapy. Glioblastoma (GBM) is the most aggressive primary malignant brain cancer in adults. Imaging methods such as positron emission tomography (PET) and different magnetic resonance imaging (MRI) techniques are highly valuable for the diagnosis and therapeutic evaluation of GBM and other malignant brain tumors. However, differentiating between tumor tissue and inflamed brain tissue with imaging protocols remains a challenge. Here, we review recent advances in imaging methods that have helped to improve the specificity of primary tumor diagnosis versus evaluation of inflamed and necrotic brain lesions. We also comment on advances in differentiating metastasis from neuroinflammation processes. Recent advances include the radiosynthesis of 18 F-FIMP, an L-type amino acid transporter 1 (LAT1)specific PET probe that allows clearer differentiation between tumor tissue and inflammation compared to previous probes, and the combination of different advanced imaging protocols with the inclusion of radiomics and machine learning algorithms.

show abstract

Section: Neuroinflammation As a Consequence Of Gbm Treatmentmentioning

confidence: 99%

Section: Imaging Advances For the Evaluation Of Brain Tumors And Neuroinflammationmentioning

confidence: 99%

Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches

Roesler

Dini²,

Isolan³

2021

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…( 18 F)FET is employed for brain tumor imaging, and is a powerful tool to discriminate recurrent glioblastoma from the posttreatment brain changes and to predict overall survival in glioblastoma patients [ 231 ]. Verhoeven et al reported 2-( 18 F)-2-fluoroethyl-l-phenylalanine, 2-( 18 F)FELP as a new SLC7A5-targeting PET tracer for glioblastoma that is predominantly transported by the SLC7A5 and can discriminate glioblastoma from the radiation necrosis even better than ( 18 F)FET [ 219 , 220 ]. Nozaki et al identified SLC7A5 specific PET tracer, (S)-2-amino-3-[3-(2- 18 F-fluoroethoxy)-4-iodophenyl]-2-methylpropanoic acid, or 18 F-FIMP.…”

Section: Molecular Imaging By Using Amino Acid Transportersmentioning

confidence: 99%

Amino Acid Transporters on the Guard of Cell Genome and Epigenome

Kahya

Köseer

Dubrovska

2021

Cancers

View full text Add to dashboard Cite

Tumorigenesis is driven by metabolic reprogramming. Oncogenic mutations and epigenetic alterations that cause metabolic rewiring may also upregulate the reactive oxygen species (ROS). Precise regulation of the intracellular ROS levels is critical for tumor cell growth and survival. High ROS production leads to the damage of vital macromolecules, such as DNA, proteins, and lipids, causing genomic instability and further tumor evolution. One of the hallmarks of cancer metabolism is deregulated amino acid uptake. In fast-growing tumors, amino acids are not only the source of energy and building intermediates but also critical regulators of redox homeostasis. Amino acid uptake regulates the intracellular glutathione (GSH) levels, endoplasmic reticulum stress, unfolded protein response signaling, mTOR-mediated antioxidant defense, and epigenetic adaptations of tumor cells to oxidative stress. This review summarizes the role of amino acid transporters as the defender of tumor antioxidant system and genome integrity and discusses them as promising therapeutic targets and tumor imaging tools.

show abstract

“…Alterations in the integrity of the blood-brain barrier in inflamed sites leads to immune cell infiltration, fluid transudation into the interstitial space and brain edema. Infiltrated immune cells as well as reactive glial cells increase expression of mediators, amplifying the response [31,[34][35][36].…”

Section: Neuroinflammation As a Consequence Of Gbm Treatmentmentioning

confidence: 99%

“…A study with 50 patients showed that ( 11 )C-methionine-PET was superior to both ( 11 )C-choline and ( 18)F-FDG -PET for distinguishing GBM recurrence from radiation necrosis [53]. The LAT1 tumor-specific PET tracer 2-[ 18 F]FELP PET is able to differentiate glioblastoma from radiation necrosis, and 2-[ 18 F]FELP uptake is less likely to be contaminated by the presence of inflammation than the [ 18 F]FDG signal [35].…”

Section: Imaging Advances For the Evaluation Of Brain Tumors And Neuroinflammationmentioning

confidence: 99%

Brain tumours, brain metastases, and neuroinflammation: Insights from neuroimaging studies.

Roesler

Dini²,

Isolan³

2021

Preprint

View full text Add to dashboard Cite

Brain tumors and brain metastases induce changes in brain tissue remodelling that lead to immunosuppression and trigger an inflammatory response within the tumor microenvironment. These immune and inflammatory changes can influence invasion and metastasis. Other neuroinflammatory and necrotic lesions may occur in patients with brain cancer or brain metastases as sequelae from treatment with radiotherapy. Glioblastoma (GBM) is the most aggressive primary malignant brain cancer in adults. Imaging methods such as positron-emission tomography (PET) and different magnetic resonance imaging (MRI) techniques are highly valuable for the diagnosis and therapeutic evaluation of GBM and other malignant brain tumors. However, differentiating between tumor tissue and inflamed brain tissue with imaging protocols remains a challenge. Here, we review recent advances in imaging methods that have helped to improve the specificity of primary tumor diagnosis versus evaluation of inflamed and necrotic brain lesions. We also comment on advances in differentiating metastasis from neuroinflammation processes. Recent advances include the radiosynthesis of 18F-FIMP, an L-type amino acid transporter 1 (LAT1)-specific PET probe that allows better differentiation between tumor tissue and inflammation compared to previous probes; and the combination different advanced imaging protocols with the inclusion of radiomics and machine learning algorithms.

show abstract

2-[18F]FELP, a novel LAT1-specific PET tracer, for the discrimination between glioblastoma, radiation necrosis and inflammation

Cited by 12 publications

References 40 publications

Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches

Neuroinflammation and immunoregulation in glioblastoma and brain metastases: Recent developments in imaging approaches

Amino Acid Transporters on the Guard of Cell Genome and Epigenome

Brain tumours, brain metastases, and neuroinflammation: Insights from neuroimaging studies.

Contact Info

Product

Resources

About